The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Official Title: Phase I Study of Simmitecan Hydrochloride for Injection in Patients With Advanced Solid Tumor:Tolerability and Pharmacokinetics
Study ID: NCT01832298
Brief Summary: RATIONAL: Simmitecan is an anticancer ester prodrug, which involves activation to chimmitecan. Chimmitecan,a novel CPT derivative, exhibited potent antitumor activities both in vitro and in vivo by inhibiting topoisomerase I. Also exerted comparable effects on topoisomerase I compared with topotecan and SN38 and possessed improved anticancer potency and pharmacologic profiles, compared with the clinically available CPT analogues. PURPOSE: to determine the maximum tolerated dose, the safety profile and pharmacokinetics of Simmitecan.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
The tumor hospital affiliated to Harbin medical university, Harbin, Heilongjiang, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Name: Jinwan Wang, M.D.
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Aiping Zhou, M.D.
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Yong Xu, M.D.
Affiliation: West China Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Qingyuan Zhang, M.D.
Affiliation: The Tumor Hospital Affiliated to Harbin Medical University
Role: PRINCIPAL_INVESTIGATOR